TY - JOUR
T1 - Herpes simplex encephalitis in adults and older children
AU - Aksamit, Allen J.
N1 - Funding Information:
A trial using oral valacyclovir after intravenous therapy with acyclovir for HSE has been organized to improve the outcome of patients with herpes encephalitis. Many patients have severe cognitive deficits [16] after herpes simplex encephalitis. Conceptually, if profound infection is associated with longer viral persistence, some deficits may be improved by longer-term therapy. This therapy trial uses a design of high-dose oral well-absorbed precursor for acyclovir, valacyclovir. The trial is sponsored by the National Institutes of Health and administered by the University of Alabama, Birmingham through the Collaborative Antiviral Study Group [19].
PY - 2005/3
Y1 - 2005/3
N2 - • Herpes simplex encephalitis (HSE) is a neurologically devastating illness associated with substantial morbidity and mortality in adults and older children. • The correct recognition of HSE, and distinguishing it from other forms of encephalitis, brain abscess or mimicking disorders early in the course of evaluation facilitates treatment decisions when neurologic complications occur. • The combination of clinical characteristics, magnetic resonance imaging of the head, and polymerase chain reaction (PCR) analysis of cerebrospinal fluid for herpes simplex type 1 DNA is a sensitive and specific way of diagnosing HSE for proper treatment. • Early treatment is essential. HSE is treated with acyclovir 10 mg/kg every 8 hours intravenously for 21 days, unless the illness is mild, or if nephrotoxicity occurs. • Whether prolonged therapy with oral antiviral treatment after standard intravenous acyclovir offers any advantage from the standpoint of neurologic morbidity or mortality is unproven. • PCR-negative typical cases and PCR-positive atypical cases of HSE can occur and require treatment with acyclovir.
AB - • Herpes simplex encephalitis (HSE) is a neurologically devastating illness associated with substantial morbidity and mortality in adults and older children. • The correct recognition of HSE, and distinguishing it from other forms of encephalitis, brain abscess or mimicking disorders early in the course of evaluation facilitates treatment decisions when neurologic complications occur. • The combination of clinical characteristics, magnetic resonance imaging of the head, and polymerase chain reaction (PCR) analysis of cerebrospinal fluid for herpes simplex type 1 DNA is a sensitive and specific way of diagnosing HSE for proper treatment. • Early treatment is essential. HSE is treated with acyclovir 10 mg/kg every 8 hours intravenously for 21 days, unless the illness is mild, or if nephrotoxicity occurs. • Whether prolonged therapy with oral antiviral treatment after standard intravenous acyclovir offers any advantage from the standpoint of neurologic morbidity or mortality is unproven. • PCR-negative typical cases and PCR-positive atypical cases of HSE can occur and require treatment with acyclovir.
UR - http://www.scopus.com/inward/record.url?scp=14744287243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=14744287243&partnerID=8YFLogxK
U2 - 10.1007/s11940-005-0023-1
DO - 10.1007/s11940-005-0023-1
M3 - Review article
AN - SCOPUS:14744287243
SN - 1092-8480
VL - 7
SP - 145
EP - 150
JO - Current Treatment Options in Neurology
JF - Current Treatment Options in Neurology
IS - 2
ER -